News
Labeling for Several HIV Meds Updated to Include Interaction Data With DOACs
If Tybost is given with atazanavir or darunavir, coadministration with rivaroxaban is not recommended due to a potentially increased bleeding risk.
Your search for dabigatran returned 13 results
News
Many AKI Reports in FAERS Linked to Drugs Not Recognized as Nephrotoxic
According to the authors, this is the first study to identify medications most commonly reported for a specific adverse reaction using this database.
News
Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent
Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
ACC.18
Dabigatran Cuts Risk of Major CV Complications in Patients With MINS
The primary efficacy outcome was the combined rate of death from a cardiovascular cause, heart attack, stroke due to inadequate blood supply, blood clots or amputation due to cardiovascular disease.
News
Comparison of Oral Anticoagulants for Preventing Stroke in AF
The greatest risk reduction of stroke or systemic embolism was seen with dabigatran 150mg twice daily (odds ratio [OR] 0.65, 95% CI: 0.52-0.81), followed by apixaban 5mg twice daily (OR 0.79, 95% CI: 0.66-0.94).
AHA 2017 Scientific Sessions
Direct Oral Anticoagulant Use Increasing in Dialysis Patients With AFib
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
ESC 2017
Bleeding Risk Reduced with Dabigatran Dual Tx vs. Warfarin Triple Tx
The primary safety endpoint was defined as time to major bleeding events and clinically relevant non-major bleeding events when compared to triple therapy with warfarin.
ACC.17
Anticoagulants Compared in A-fib Patients Undergoing Catheter Ablation
Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.
ACC.17
Stroke, Major Bleeding Risk Low with Dabigatran Etexilate
The data represents ~3,000 patients who had received the study drug in Phase 3 of GLORIA-AF with up to 2 years follow-up.
News
Certain Drug Classes Linked to More ED Visits for Adverse Drug Reactions
A study published in JAMA reports that anticoagulants, antibiotics, diabetes drugs, and opioids are the most common drug classes related to emergency department visits for adverse drug events in the country.
